AUROBINDO PHARMA LTD.

Aurobindo Pharma announced it has received final approval from the US FDA for Tofacitinib Tablets in 5 mg and 10 mg strengths. These tablets are bioequivalent to Xeljanz Tablets. The product will be manufactured at its subsidiary APL Healthcare Unit IV and launched immediately. The US market for Tofacitinib Tablets was approximately $494 million in April 2026. This approval brings Aurobindo's total US FDA ANDA approvals to 586. The drug is indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Aurobindo Pharma has inaugurated TheraNym, a large-scale biologics contract manufacturing organization (CMO) in Telangana, India. The facility, a subsidiary of Aurobindo Pharma, aims to meet global demand for biologic therapies and has MSD as its anchor customer. The inauguration was attended by Telangana Ministers, highlighting the government's support for the life sciences industry. TheraNym is equipped with advanced manufacturing capabilities and is designed to meet international regulatory standards, positioning Aurobindo Pharma for growth in the biologics contract manufacturing segment.

The US FDA has classified the inspection of Unit-1 of Eugia Pharma Specialities Ltd, a wholly-owned subsidiary of Aurobindo Pharma, as "Official Action Indicated" (OAI). The inspection, which took place from February 16 to February 27, 2026, concluded with 4 observations. The company has stated that the OAI classification has no impact on its financials or operations and that they are committed to maintaining the highest quality manufacturing standards.

Aurobindo Pharma Ltd announced the incorporation of a new wholly-owned stepdown subsidiary, Arrow Pharma Production SAS, in France through its stepdown subsidiary Agile Pharma BV. Arrow Pharma Production SAS was created on May 21, 2026, with an authorized capital of 100,000 EUR. The new entity will focus on expanding the manufacturing of generic formulations in France. No governmental or regulatory approvals were required for the incorporation.

Aurobindo Pharma Ltd's board approved the standalone and consolidated audited financial results for the year ended March 31, 2026. The company reported total revenue from operations of ₹111,717.2 million and a profit after tax of ₹24,148.0 million. The board also approved the resignation of M/s. MRR & Associates as Secretarial Auditor and appointed M/s. RPR & Associates as the new Secretarial Auditors. Additionally, M/s. Ernst & Young LLP were re-appointed as Internal Auditors.

Aurobindo Pharma Ltd has appointed RPR & Associates as its Secretarial Auditor for a five-year term commencing from FY 2026-27, subject to shareholder approval at the upcoming Annual General Meeting. This follows the resignation of MRR & Associates, effective May 22, 2026, due to the health issues of its sole proprietor. The board meeting, held on May 21, 2026, which approved the appointment, commenced at 4:30 p.m. and concluded at 6:25 p.m.

Aurobindo Pharma Ltd has re-appointed M/s. Ernst & Young LLP as its Internal Auditors for the period from June 2026 to May 2027. The decision was made during the Board of Directors meeting held on May 21, 2026. The re-appointment is in compliance with Regulation 30 of the SEBI Listing Regulations. The board meeting commenced at 4:30 p.m. and concluded at 6:25 p.m.

Aurobindo Pharma Ltd announced its consolidated financial results for Q4 and year ended March 31, 2026. Revenue from operations increased by 5.6% YoY to ₹8,853 Cr, with European business crossing €1bn+ in revenues in FY26. Net profit for the quarter stood at ₹921 Cr. The company received final approval for 9 ANDAs from the USFDA. Strong net cash position as on 31-Mar-26 after payment for acquisition of Khandelwal laboratories (non-oncology) business at USD 317mn.

Aurobindo Pharma Ltd's board approved the standalone and consolidated audited financial results for the fourth quarter and year ended March 31, 2026. The company reported total revenue from operations of ₹111,717.2 million for FY26. There were changes in auditors: M/s. MRR & Associates resigned as Secretarial Auditor, replaced by M/s. RPR & Associates for a five-year term, subject to shareholder approval. M/s. Ernst & Young LLP were re-appointed as Internal Auditors for June 2026 to May 2027.

The Hon'ble High Court of Telangana, Hyderabad, dismissed a writ petition filed by promoters of Aurobindo Pharma, including Mr. P. V. Ramprasad Reddy, Ms. P. Suneela Rani, Mr. Kambam Prasad Reddy, and Trident Chemphar Limited. The petition sought to set aside an Impugned Communication from SEBI directing the promoters to deposit profits of ₹6.53 crores plus interest related to alleged insider trading violations. The order was issued on May 6, 2026, and received on May 15, 2026. The promoters will decide on future actions in consultation with legal advisors. The company states the order has no impact on its financials or operations.